Want to see GPCR full AI Analyst Report?
Top Page
Structure Therapeutics, Inc. Sponsored ADR
(NASDAQ:GPCR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$22.00
▼(-55.93% Downside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by weak financial operating performance (pre-revenue with widening losses and meaningful cash burn) and a strongly bearish technical trend (price below major moving averages with negative momentum). These are partially offset by a strong balance sheet with minimal leverage and a favorable corporate update highlighting positive clinical data and progressing late-stage development.
Positive Factors
Low Financial Leverage
Minimal leverage reduces refinancing risk and preserves financial flexibility while the company funds clinical development. The strongly positive equity base provides a cushion against operating losses and leaves more strategic room to advance programs without substantial debt-service demands.
Negative Factors
Pre-Revenue Business Model
With no commercial product revenue, the company has not yet established a self-funding operating model. Its ability to create durable value therefore remains dependent on clinical and regulatory execution before product sales or recurring partner economics can begin.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Minimal leverage reduces refinancing risk and preserves financial flexibility while the company funds clinical development. The strongly positive equity base provides a cushion against operating losses and leaves more strategic room to advance programs without substantial debt-service demands.
Read all positive factors
Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.63B
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth1.47%
CountryUS
Employees281
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.03
Shares Outstanding71,309,860
10 Day Avg. Volume1,305,536
30 Day Avg. Volume1,408,291
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.10K
Enterprise Value/Ebitda-12.06
Forecast
1Y Price Target
$108.46Price Target Upside117.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.67
Revenue Forecast (FY)$35.71M
Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model
Company Description
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment opt...
How the Company Makes Money
Structure Therapeutics is a clinical-stage biotechnology company and therefore does not typically generate material, recurring revenue from commercial product sales because its drug candidates are still in development. To the extent the company ge...
Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -212.46M | -139.35M | -121.22M | -75.70M | -51.03M | -37.62M |
| Net Income | -215.06M | -141.20M | -122.53M | -89.62M | -51.32M | -40.01M |
Balance Sheet | ||||||
| Total Assets | 1.43B | 1.58B | 903.33M | 482.02M | 97.84M | 111.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.34B | 1.45B | 883.52M | 467.32M | 90.84M | 107.31M |
| Total Debt | 6.23M | 6.49M | 3.86M | 5.45M | 260.00K | 621.00K |
| Total Liabilities | 71.01M | 67.54M | 38.49M | 29.05M | 212.99M | 175.89M |
| Stockholders Equity | 1.35B | 1.52B | 864.84M | 452.97M | -115.14M | -64.73M |
Cash Flow | ||||||
| Free Cash Flow | -224.46M | -225.81M | -117.93M | -81.66M | -46.27M | -33.37M |
| Operating Cash Flow | -220.25M | -222.20M | -116.64M | -79.49M | -46.12M | -32.16M |
| Investing Cash Flow | -417.11M | 89.80M | -358.91M | -268.34M | -62.11M | 17.86M |
| Financing Cash Flow | 761.53M | 762.52M | 515.26M | 451.53M | 29.01M | 103.25M |
Structure Therapeutics, Inc. Sponsored ADR Technical Analysis
Negative
49.92
Price Trends
37.92
Negative
42.86
Negative
50.79
Negative
Market Momentum
-4.61
Negative
21.80
Positive
25.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Negative. The current price of 49.92 is above the 20-day moving average (MA) of 26.94, above the 50-day MA of 37.92, and below the 200-day MA of 50.79, indicating a bearish trend. The MACD of -4.61 indicates Negative momentum. The RSI at 21.80 is Positive, neither overbought nor oversold. The STOCH value of 25.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GPCR.
Structure Therapeutics, Inc. Sponsored ADR Risk Analysis
Structure Therapeutics, Inc. Sponsored ADR disclosed 102 risk factors in its most recent earnings report. Structure Therapeutics, Inc. Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Structure Therapeutics, Inc. Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.84B | -75.48 | -6.31% | ― | 13520.11% | 74.95% | |
58 Neutral | $3.40B | -5.66 | -94.56% | ― | ― | -203.77% | |
52 Neutral | $1.63B | -7.26 | -16.91% | ― | ― | 1.47% | |
52 Neutral | $2.60B | -22.47 | -26.01% | ― | ― | -4.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $703.03M | -10.37 | -40.40% | ― | -29.03% | 54.11% |
* Healthcare Sector Average
GPCR
Structure Therapeutics, Inc. Sponsored ADR
21.93
-4.63
-17.43%
LXRX
Lexicon Pharmaceuticals
1.49
0.09
6.43%
VKTX
Viking Therapeutics
25.83
-8.09
-23.85%
MBX
MBX Biosciences, Inc.
50.46
34.33
212.83%
SEPN
Septerna, Inc.
40.88
19.09
87.61%
KLRA
Kailera Therapeutics, Inc.
13.27
-12.73
-48.96%
Structure Therapeutics, Inc. Sponsored ADR Corporate Events
Business Operations and StrategyProduct-Related Announcements
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results
Positive
Sep 8, 2026
On September 8, 2026, Structure Therapeutics reported positive topline data from a Phase 1/2a single ascending dose study of ACCG-2671 in healthy adults without obesity, showing a roughly six-day half-life, dose-proportional pharmacokinetics and n...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.